These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35110681)

  • 21. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group.
    Kopp LM; Malempati S; Krailo M; Gao Y; Buxton A; Weigel BJ; Hawthorne T; Crowley E; Moscow JA; Reid JM; Villalobos V; Randall RL; Gorlick R; Janeway KA
    Eur J Cancer; 2019 Nov; 121():177-183. PubMed ID: 31586757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GPNMB expression in uveal melanoma: a potential for targeted therapy.
    Williams MD; Esmaeli B; Soheili A; Simantov R; Gombos DS; Bedikian AY; Hwu P
    Melanoma Res; 2010 Jun; 20(3):184-90. PubMed ID: 20375921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gpnmb/osteoactivin, an attractive target in cancer immunotherapy.
    Zhou LT; Liu FY; Li Y; Peng YM; Liu YH; Li J
    Neoplasma; 2012; 59(1):1-5. PubMed ID: 22017590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504).
    Khan SA; Sun Z; Dahlberg S; Malhotra J; Keresztes R; Ikpeazu C; Ma P; Ramalingam SS; Pillai R
    JTO Clin Res Rep; 2021 May; 2(5):100166. PubMed ID: 34590018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma.
    Hasanov M; Rioth MJ; Kendra K; Hernandez-Aya L; Joseph RW; Williamson S; Chandra S; Shirai K; Turner CD; Lewis K; Crowley E; Moscow J; Carter B; Patel S
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32823698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycoprotein nmb Is Exposed on the Surface of Dormant Breast Cancer Cells and Induces Stem Cell-like Properties.
    Chen C; Okita Y; Watanabe Y; Abe F; Fikry MA; Ichikawa Y; Suzuki H; Shibuya A; Kato M
    Cancer Res; 2018 Nov; 78(22):6424-6435. PubMed ID: 30224376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate.
    Qian X; Mills E; Torgov M; LaRochelle WJ; Jeffers M
    Mol Oncol; 2008 Jun; 2(1):81-93. PubMed ID: 19383330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lysosomal stress in obese adipose tissue macrophages contributes to MITF-dependent Gpnmb induction.
    Gabriel TL; Tol MJ; Ottenhof R; van Roomen C; Aten J; Claessen N; Hooibrink B; de Weijer B; Serlie MJ; Argmann C; van Elsenburg L; Aerts JM; van Eijk M
    Diabetes; 2014 Oct; 63(10):3310-23. PubMed ID: 24789918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.
    Kuan CT; Wakiya K; Dowell JM; Herndon JE; Reardon DA; Graner MW; Riggins GJ; Wikstrand CJ; Bigner DD
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1970-82. PubMed ID: 16609006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
    Cho TM; Kim JY; Kim YJ; Sung D; Oh E; Jang S; Farrand L; Hoang VH; Nguyen CT; Ann J; Lee J; Seo JH
    Cancer Lett; 2019 Apr; 447():141-153. PubMed ID: 30703411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
    Tse KF; Jeffers M; Pollack VA; McCabe DA; Shadish ML; Khramtsov NV; Hackett CS; Shenoy SG; Kuang B; Boldog FL; MacDougall JR; Rastelli L; Herrmann J; Gallo M; Gazit-Bornstein G; Senter PD; Meyer DL; Lichenstein HS; LaRochelle WJ
    Clin Cancer Res; 2006 Feb; 12(4):1373-82. PubMed ID: 16489096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin α5β1 for efficient breast cancer metastasis.
    Maric G; Annis MG; Dong Z; Rose AA; Ng S; Perkins D; MacDonald PA; Ouellet V; Russo C; Siegel PM
    Oncogene; 2015 Oct; 34(43):5494-504. PubMed ID: 25772243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties.
    Rose AA; Annis MG; Dong Z; Pepin F; Hallett M; Park M; Siegel PM
    PLoS One; 2010 Aug; 5(8):e12093. PubMed ID: 20711474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.
    Yu S; Cai X; Wu C; Liu Y; Zhang J; Gong X; Wang X; Wu X; Zhu T; Mo L; Gu J; Yu Z; Chen J; Thiery JP; Chai R; Chen L
    Int J Biol Sci; 2017; 13(4):505-517. PubMed ID: 28529458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer.
    Kanematsu M; Futamura M; Takata M; Gaowa S; Yamada A; Morimitsu K; Morikawa A; Mori R; Hara H; Yoshida K
    Cancer Med; 2015 Sep; 4(9):1344-55. PubMed ID: 26077887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new immunochemical strategy for triple-negative breast cancer therapy.
    Lin CW; Zheng T; Grande G; Nanna AR; Rader C; Lerner RA
    Sci Rep; 2021 Jul; 11(1):14875. PubMed ID: 34290315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of the kringle-like domain in glycoprotein NMB for its tumorigenic potential.
    Xie R; Okita Y; Ichikawa Y; Fikry MA; Huynh Dam KT; Tran STP; Kato M
    Cancer Sci; 2019 Jul; 110(7):2237-2246. PubMed ID: 31127873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
    Mumin NH; Drobnitzky N; Patel A; Lourenco LM; Cahill FF; Jiang Y; Kong A; Ryan AJ
    BMC Cancer; 2019 Jan; 19(1):102. PubMed ID: 30678647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity.
    Maric G; Annis MG; MacDonald PA; Russo C; Perkins D; Siwak DR; Mills GB; Siegel PM
    Oncogene; 2019 Jun; 38(26):5294-5307. PubMed ID: 30914799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan.
    McGuinness JE; Kalinsky K
    Expert Opin Biol Ther; 2021 Jul; 21(7):903-913. PubMed ID: 33089726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.